Techniclone Announces Appointment of Terrence Chew, M.D. as Vice President, Clinical and Regulatory Affairs.TUSTIN, Calif.--(BUSINESS WIRE)--Aug. 18, 1999--
Techniclone Corporation (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : TCLN) a developer of leading-edge therapeutics for the advanced treatment of cancer, announced today the appointment of Terrence Chew, M.D., as Vice President Clinical and Regulatory Affairs, effective August 30, 1999.
Larry O. Bymaster, President and Chief Executive Officer stated, "We are very pleased that Dr. Chew is joining the Techniclone team. He brings a solid corporate and medical background in clinical development and research, including obtaining FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. approval for several drugs. As an oncologist, Dr. Chew's guidance will be invaluable in assisting the Company to maximize the progress of our Cotara(TM) clinical trials, and the preclinical programs for the Vascular Targeting Agents and Vasopermeation Enhancement Agents."
Dr. Chew is currently Vice President, Clinical Development for SkyePharma Inc., a publicly traded pharmaceutical company, where he developed and guided the clinical development program for a drug that received FDA approval. Prior to SkyePharma Inc., he was Medical Research Director at Agouron Pharmaceuticals. Previous to this, Dr. Chew held clinical research and medical positions with Johnson & Johnson Company and Rhone-Poulenc Roer Corporation. In addition to his academic experience that includes positions as Medical Director at Saint Francis Memorial Hospital Saint Francis Memorial Hospital (SFMH) is a hospital in San Francisco, California, USA. It is currently operated by Catholic Healthcare West. History
Founded just over a century ago in San Francisco by five physicians, they undertook to build "the most up-to-date modern , and Assistant Clinical Professor (Oncology) at University of California, Davis The University of California, Davis, commonly known as UC Davis, is one of the ten campuses of the University of California, and was established as the University Farm in 1905. , Dr. Chew also spent 14 years in the private practice of oncology and hematology. He holds a Bachelors Degree in Biochemistry from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal , and received his M.D. from the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. .
Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercializing and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral technologies: Cotara(TM) Vasopermeation Enhancement Agents (VEA VEA Virginia Education Association
VEA Virtual Environment Architecture
VEA Value Engineering Analysis
VEA video encryption algorithm
VEA Value Efficiency Analysis
VEA Vida Ecología y Ambiente (Spanish, Guatemala) ), and Vascular Targeting Agents (VTA). Cotara(TM), which binds to dead/decaying cells found in the core of solid tumors, is presently in a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored
phase II in the U.S. for malignant glioma glioma /gli·o·ma/ (gli-o´mah) a tumor composed of neuroglia in any of its states of development; sometimes extended to include all intrinsic neoplasms of the brain and spinal cord, as astrocytomas, ependymomas, etc. (brain cancer), and a Phase I/II clinical trial in Mexico City for the treatment of pancreatic, prostate and liver cancer. VEA's are monoclonal antibodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutic agents versus normal tissues, while VTA's are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTA's can also deliver a wide variety of therapeutic agents to a solid tumor, including biologic agents, toxins and radioisotopes. The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma which was recently licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing.
Additional information on the Company and its products can be found at www.techniclone.com.
Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10Q for the quarter ended January 31, 1999 and Form 10K for the year ended April 30, 1998.